These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

578 related articles for article (PubMed ID: 34711906)

  • 1. Hope for patients with neuromyelitis optica spectrum disorders - from mechanisms to trials.
    Pittock SJ; Zekeridou A; Weinshenker BG
    Nat Rev Neurol; 2021 Dec; 17(12):759-773. PubMed ID: 34711906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies.
    Carnero Contentti E; Correale J
    J Neuroinflammation; 2021 Sep; 18(1):208. PubMed ID: 34530847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management.
    Kümpfel T; Giglhuber K; Aktas O; Ayzenberg I; Bellmann-Strobl J; Häußler V; Havla J; Hellwig K; Hümmert MW; Jarius S; Kleiter I; Klotz L; Krumbholz M; Paul F; Ringelstein M; Ruprecht K; Senel M; Stellmann JP; Bergh FT; Trebst C; Tumani H; Warnke C; Wildemann B; Berthele A;
    J Neurol; 2024 Jan; 271(1):141-176. PubMed ID: 37676297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder.
    Nie T; Blair HA
    CNS Drugs; 2022 Oct; 36(10):1133-1141. PubMed ID: 36070074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of treatments in Neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature.
    Velasco M; Zarco LA; Agudelo-Arrieta M; Torres-Camacho I; Garcia-Cifuentes E; Muñoz O
    Mult Scler Relat Disord; 2021 May; 50():102869. PubMed ID: 33711580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Network Meta-analysis of Ravulizumab and Alternative Interventions for the Treatment of Neuromyelitis Optica Spectrum Disorder.
    Clardy SL; Pittock SJ; Aktas O; Nakahara J; Isobe N; Centonze D; Fam S; Kielhorn A; Yu JC; Jansen J; Zhang I
    Neurol Ther; 2024 Jun; 13(3):535-549. PubMed ID: 38722571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder.
    Fung S; Shirley M
    CNS Drugs; 2023 Apr; 37(4):363-370. PubMed ID: 36933107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder.
    Wingerchuk DM; Zhang I; Kielhorn A; Royston M; Levy M; Fujihara K; Nakashima I; Tanvir I; Paul F; Pittock SJ
    Neurol Ther; 2022 Mar; 11(1):123-135. PubMed ID: 34773597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging Targeted Therapies for Neuromyelitis Optica Spectrum Disorders.
    Valencia-Sanchez C; Wingerchuk DM
    BioDrugs; 2021 Jan; 35(1):7-17. PubMed ID: 33301078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in the long-term treatment of neuromyelitis optica spectrum disorder.
    Anderson M; Levy M
    J Cent Nerv Syst Dis; 2024; 16():11795735241231094. PubMed ID: 38312734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
    Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
    Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inebilizumab for treatment of neuromyelitis optica spectrum disorder.
    J Tullman M; Zabeti A; Vuocolo S; Dinh Q
    Neurodegener Dis Manag; 2021 Oct; 11(5):341-352. PubMed ID: 34486379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the complement system in neuromyelitis optica spectrum disorder.
    Asavapanumas N; Tradtrantip L; Verkman AS
    Expert Opin Biol Ther; 2021 Aug; 21(8):1073-1086. PubMed ID: 33513036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Satralizumab in the treatment of neuromyelitis optica spectrum disorder.
    Duchow A; Bellmann-Strobl J
    Neurodegener Dis Manag; 2021 Feb; 11(1):49-59. PubMed ID: 33167776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update on biologic treatments for neuromyelitis optica spectrum disorder.
    Kim W; Kim HJ
    Expert Rev Clin Immunol; 2023 Jan; 19(1):111-121. PubMed ID: 36414430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibody therapies for aquaporin-4-immunoglobulin G-positive neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease.
    Tisavipat N; Juan HY; Chen JJ
    Saudi J Ophthalmol; 2024; 38(1):2-12. PubMed ID: 38628414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders.
    Duchow A; Paul F; Bellmann-Strobl J
    Expert Opin Biol Ther; 2020 Sep; 20(9):1061-1072. PubMed ID: 32228250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Monoclonal Antibody Therapy in Neuromyelitis Optica Spectrum Disorders: Evidence from Randomized Controlled Trials.
    Xue T; Yang Y; Lu Q; Gao B; Chen Z; Wang Z
    Mult Scler Relat Disord; 2020 Aug; 43():102166. PubMed ID: 32442886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in the treatment of neuromyelitis optica spectrum disorders.
    Romeo AR
    Curr Opin Rheumatol; 2021 May; 33(3):233-239. PubMed ID: 33741809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Satralizumab as an add-on treatment in refractory pediatric AQP4-antibody-positive neuromyelitis optica spectrum disorder: a case report.
    Li X; Wu W; Zeng Y; Wu W; Hou C; Zhu H; Liao Y; Tian Y; Chen Z; Peng B; Chen WX
    Front Immunol; 2023; 14():1257955. PubMed ID: 37915570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.